IMPROVE-DiCE:Ninerafaxstat 在心脏代谢综合征患者中的 2a 期试验
IMPROVE-DiCE 是一项两部分、开放标签、2a 期试验,评估 ninerafaxstat 改善心脏能量代谢的安全性与有效性。结果显示药物安全耐受,并改善心肌能量代谢、运动能力和症状。
要点
- Ninerafaxstat 在 2 型糖尿病合并肥胖患者中安全耐受。
- 治疗改善心肌磷酸肌酸/ATP 比值,伴或不伴 HFpEF 均一致。
- 伴 HFpEF 者运动能力和 NYHA 症状负担亦改善。
核心结论
- Ninerafaxstat 安全耐受,并改善肥胖合并糖尿病(伴或不伴 HFpEF)患者的心肌能量代谢。
研究设计与样本
- 两部分、开放标签、2a 期试验;第一部分 21 例无 HFpEF 的 2 型糖尿病合并肥胖患者治疗 4–8 周,第二部分 21 例合并 HFpEF 者治疗 12 周。
- 主要结局为心肌磷酸肌酸/ATP 比值,用磁共振成像及 31P/1H 磁共振波谱评估。
主要发现
- 第一部分:治疗与 PCr/ATP 改善相关(+0.39±0.49,95%CI 0.16–0.62;Cohen's d 0.79;P=0.002),心肌甘油三酯降低 34%(P=0.03)。
- 第二部分:治疗与 PCr/ATP 改善相关(+0.15±0.25,95%CI 0.03–0.26;Cohen's d 0.60;P=0.02)。
- 第二部分:运动时收缩期增强改善(+1.4 L/min,P=0.04),6 分钟步行距离增加 16 m(P=0.02),NYHA 症状负担改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report IMPROVE-DiCE (Improve Diabetic Cardiac Energetics), a 2-part open-label, phase 2a trial evaluating the safety and effectiveness of ninerafaxstat, a novel therapeutic designed to enhance cardiac energetics. Between May and September 2021, part 1 enrolled patients with type 2 diabetes and obesity without heart failure with preserved ejection fraction (HFpEF). Between January 2023 and June 2024, part 2 enrolled patients with type 2 diabetes, obesity, and HFpEF. METHODS: Forty-two participants received 200 mg ninerafaxstat twice daily (part 1, n=21, 43% women, 72±0.5 years of age, 4-8 weeks; part 2, n=21, 29% women, 71±6 years of age, 12 weeks). Myocardial energetics (phosphocreatine-to-ATP ratio [PCr/ATP], primary outcome) and function (rest and dobutamine stress) were assessed before and after treatment using magnetic resonance imaging, 31P- and 1H magnetic resonance spectroscopy. In part 1, hyperpolarized [1-13C]pyruvate magnetic resonance spectroscopy to assess in vivo pyruvate dehydrogenase flux (n=9) and plasma metabolomics and proteomics were also performed. RESULTS: In part 1, in patients with diabetes and obesity but without HFpEF, the heart was characterized by impaired pyruvate dehydrogenase flux, reduced PCr/ATP, triglyceride deposition, and diastolic impairment. Treatment with ninerafaxstat was associated with improved PCr/ATP (+0.39±0.49 [95% CI, 0.16-0.62]; Cohen's d, 0.79; P=0.002) and lower myocardial triglyceride (by 34%, P=0.03). In part 2, in patients with diabetes, obesity, and symptomatic HFpEF, the heart was characterized by reduced PCr/ATP, diastolic impairment, and failure of systolic augmentation to exercise. Consistently, treatment with ninerafaxstat was associated with improvement in PCr/ATP (+0.15±0.25 [95% CI, 0.03-0.26]; Cohen's d, 0.60; P=0.02), improved systolic augmentation to exercise (+1.4 L/min, P=0.04), improved exercise capacity (6-minute walk distance +16 m, P=0.02), and improved New York Heart Association class symptom burden. CONCLUSIONS: These mechanistic phase 2a study results show that ninerafaxstat is safely tolerated and improves myocardial energetics in participants with obesity and diabetes without or with clinically manifest HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04826159.
引用
- Hundertmark MJ, Birkhoelzer SM, Portwood C, et al. IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes. Circulation. 2025. PMID: 41410037. doi:10.1161/CIRCULATIONAHA.125.074041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。